Status:
UNKNOWN
Prediction of Benefit From Adjuvant Chemotherapy for pT1N1 Gastric Cancer
Lead Sponsor:
Yonsei University
Conditions:
Gastric Cancer
Eligibility:
All Genders
20-85 years
Brief Summary
To conduct a retrospective study to prove a hypothesis of "adjuvant chemotherapy provides survival benefit for patients of CTX-benefit group in gastric cancer of pT1N1, especially in high-risk group"....
Eligibility Criteria
Inclusion
- Pathologically confirmed gastric adenocarcinoma
- Patients who received R0 resection with curative intent surgery
- pT1 (mucosa/submucosa) N1(one or two metastatic lymph nodes) M0
- patients received surgery with lymph node dissection of D1 + or more
- number of retrieved lymph nodes \>15
- Formalin-Fixed Paraffin-Embedded cancer tissues are available
- Adults over 19 years
Exclusion
- Patients received pre-operative chemotherapy or radiotherapy
- Cancer in remnant stomach (history of gastrectomy)
- in hospital mortality or died within 30 days after surgery
- FFPE is not available
Key Trial Info
Start Date :
November 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2019
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03485105
Start Date
November 1 2017
End Date
November 1 2019
Last Update
April 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Upper Gastrointestinal Surgery, Department of Surgery, Yonsei University College of Medicine
Seoul, South Korea, 03722